This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Byondis B.v.. Active years: 2022-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2023
Title: Hanke Lottie Matlung: Innovator in Anti-Cancer Therapy
Introduction
Hanke Lottie Matlung is a prominent inventor based in Amsterdam, Netherlands. She has made significant contributions to the field of anti-cancer therapy through her innovative research and development of antibodies. With a total of 2 patents, her work focuses on advancing treatment options for various types of cancer.
Latest Patents
Matlung's latest patents include the development of anti-SIRPα antibodies. These antibodies are designed to be effective in anti-cancer therapy, specifically targeting human solid tumors and hematological malignancies. The invention emphasizes the use of these antibodies in combination with other anti-cancer therapies to enhance treatment efficacy. Notably, the anti-SIRPα antibodies exhibit superior specificity and affinity for both SIRPα1 and SIRPαBIT, while avoiding binding to SIRPγ and SIRPβ1v1 in certain embodiments.
Career Highlights
Hanke Lottie Matlung is currently associated with Byondis B.V., a company dedicated to developing innovative therapies for cancer treatment. Her work at Byondis has positioned her as a key player in the field of biopharmaceuticals, contributing to the advancement of targeted therapies.
Collaborations
Matlung collaborates with esteemed colleagues such as Gijsbertus Franciscus Maria Verheijden and Gerard Rouwendal. These collaborations enhance the research and development efforts at Byondis, fostering an environment of innovation and scientific discovery.
Conclusion
Hanke Lottie Matlung's contributions to anti-cancer therapy through her patented inventions highlight her role as a leading inventor in the field. Her work continues to pave the way for new treatment options that can significantly impact patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile